Metabolic Associated Fatty Liver Disease in Children and Adolescents : Mechanisms of a Silent Epidemic and Therapeutic Options
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Non-alcoholic fatty liver disease (NAFLD) is now identified as a hepatic sign of metabolic syndrome and is the most frequent cause of chronic liver disease in all ages. It is assumed that a genetic predisposition associated with epigenetic factors participates in the evolution of this condition. Visceral obesity and insulin resistance (IR) have always been considered the most important causative factors of Metabolic Syndrome (MetS) and NAFLD, but currently, the interaction between genetic heritage and environmental factors is increasingly considered fundamental in the genesis of metabolic disorders associated with NAFLD. In fact, in patients with NAFLD, insulin resistance, arterial hypertension, abdominal obesity, dyslipidemia and reduced intestinal permeability have often been found, as well as a higher prevalence of coronary artery disease, obstructive sleep apnea, polycystic ovary syndrome and osteopenia, which define a MetS framework. Early diagnosis is needed to prevent disease progression through primarily lifestyle interventions. Unfortunately, at present, there are no molecules recommended for pediatric patients. However, several new drugs are in clinical trials. For this reason, targeted studies on the interaction between genetics and environmental factors involved in the development of NAFLD and MetS and on the pathogenetic mechanisms that determine the evolution in non-alcoholic steatohepatitis (NASH), should be implemented. Therefore, it is desirable that future studies may be useful in identifying patients at risk of developing NAFLD and MetS early.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
---|---|
Enthalten in: |
Current pediatric reviews - 20(2024), 3 vom: 08., Seite 296-304 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Mosca, Antonella [VerfasserIn] |
---|
Links: |
---|
Themen: |
DHA |
---|
Anmerkungen: |
Date Completed 30.01.2024 Date Revised 30.01.2024 published: Print Citation Status MEDLINE |
---|
doi: |
10.2174/1573396319666230403121805 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM355182076 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM355182076 | ||
003 | DE-627 | ||
005 | 20240130232003.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2174/1573396319666230403121805 |2 doi | |
028 | 5 | 2 | |a pubmed24n1275.xml |
035 | |a (DE-627)NLM355182076 | ||
035 | |a (NLM)37013431 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Mosca, Antonella |e verfasserin |4 aut | |
245 | 1 | 0 | |a Metabolic Associated Fatty Liver Disease in Children and Adolescents |b Mechanisms of a Silent Epidemic and Therapeutic Options |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 30.01.2024 | ||
500 | |a Date Revised 30.01.2024 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
520 | |a Non-alcoholic fatty liver disease (NAFLD) is now identified as a hepatic sign of metabolic syndrome and is the most frequent cause of chronic liver disease in all ages. It is assumed that a genetic predisposition associated with epigenetic factors participates in the evolution of this condition. Visceral obesity and insulin resistance (IR) have always been considered the most important causative factors of Metabolic Syndrome (MetS) and NAFLD, but currently, the interaction between genetic heritage and environmental factors is increasingly considered fundamental in the genesis of metabolic disorders associated with NAFLD. In fact, in patients with NAFLD, insulin resistance, arterial hypertension, abdominal obesity, dyslipidemia and reduced intestinal permeability have often been found, as well as a higher prevalence of coronary artery disease, obstructive sleep apnea, polycystic ovary syndrome and osteopenia, which define a MetS framework. Early diagnosis is needed to prevent disease progression through primarily lifestyle interventions. Unfortunately, at present, there are no molecules recommended for pediatric patients. However, several new drugs are in clinical trials. For this reason, targeted studies on the interaction between genetics and environmental factors involved in the development of NAFLD and MetS and on the pathogenetic mechanisms that determine the evolution in non-alcoholic steatohepatitis (NASH), should be implemented. Therefore, it is desirable that future studies may be useful in identifying patients at risk of developing NAFLD and MetS early | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a DHA | |
650 | 4 | |a Metabolic Syndrome | |
650 | 4 | |a NAFL | |
650 | 4 | |a NASH | |
650 | 4 | |a probiotics | |
650 | 4 | |a uric acid | |
650 | 4 | |a vitamin D. | |
700 | 1 | |a Volpe, Luca Della |e verfasserin |4 aut | |
700 | 1 | |a Sartorelli, Maria Rita |e verfasserin |4 aut | |
700 | 1 | |a Comparcola, Donatella |e verfasserin |4 aut | |
700 | 1 | |a Veraldi, Silvio |e verfasserin |4 aut | |
700 | 1 | |a Alisi, Anna |e verfasserin |4 aut | |
700 | 1 | |a Maggiore, Giuseppe |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current pediatric reviews |d 2015 |g 20(2024), 3 vom: 08., Seite 296-304 |w (DE-627)NLM365873055 |x 1875-6336 |7 nnns |
773 | 1 | 8 | |g volume:20 |g year:2024 |g number:3 |g day:08 |g pages:296-304 |
856 | 4 | 0 | |u http://dx.doi.org/10.2174/1573396319666230403121805 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 20 |j 2024 |e 3 |b 08 |h 296-304 |